{"result": "{\n    \"title\": \"Global Septic Shock Clinical Trials Network\",\n    \"summary\": \"This report focuses on the interconnected network of entities involved in clinical trials for septic shock treatments, highlighting the roles of PLACEBO, DROTAA, the ADRENAL trial, and significant contributions from countries like Australia and New Zealand. It explores the impact of these trials on medical research and patient care, emphasizing the global collaboration in seeking effective treatments for septic shock.\",\n    \"rating\": 7.5,\n    \"rating_explanation\": \"The impact severity rating is high due to the critical nature of septic shock treatment research and its potential to save lives worldwide.\",\n    \"findings\": [\n        {\n            \"summary\": \"PLACEBO's pivotal role in clinical trials\",\n            \"explanation\": \"PLACEBO serves as a fundamental control in the rigorous assessment of new treatments for septic shock, allowing researchers to distinguish between the true efficacy of treatments and placebo effects. Its use across multiple studies, including those comparing it against hydrocortisone and DROTAA, underscores its importance in establishing the validity of clinical research findings. The consistent application of PLACEBO in trials across various countries, including Australia and New Zealand, highlights its universal acceptance as a critical component of clinical research methodology [Data: Entities (12), Relationships (16, 117, 110, +more)].\"\n        },\n        {\n            \"summary\": \"The significance of the ADRENAL trial\",\n            \"explanation\": \"The ADRENAL trial represents a key study in the quest to improve septic shock treatment, testing the hypothesis that hydrocortisone reduces mortality among patients. This trial's global reach, with sites in countries such as Australia, New Zealand, the United Kingdom, and Saudi Arabia, illustrates the international effort to address septic shock, a condition with high mortality rates. The involvement of prestigious research institutions and funding from national health councils further emphasize the trial's importance in the medical research community [Data: Entities (53, 54, 235, 236, +more)].\"\n        },\n        {\n            \"summary\": \"DROTAA's impact on septic shock treatment research\",\n            \"explanation\": \"DROTAA, once considered a promising treatment for septic shock, was subjected to rigorous testing against PLACEBO. The findings, indicating DROTAA's ineffectiveness, highlight the critical role of evidence-based medicine in guiding treatment protocols. This outcome not only influenced the direction of subsequent research but also underscored the necessity of placebo-controlled trials in validating treatment efficacy. The involvement of multiple countries in the DROTAA trials reflects the global commitment to improving septic shock outcomes [Data: Entities (11), Relationships (12, 98, 90, +more)].\"\n        },\n        {\n            \"summary\": \"Australia and New Zealand's contributions to septic shock research\",\n            \"explanation\": \"Australia and New Zealand have been instrumental in advancing septic shock research, hosting numerous critical trials, including the ADRENAL and ARISE studies. Their extensive medical research infrastructure, exemplified by the participation of multiple ICU sites and the support of national research councils, has facilitated significant contributions to the global understanding of septic shock. These countries' active engagement in international clinical research efforts underscores their commitment to improving patient care and outcomes in critical care settings [Data: Entities (16, 17), Relationships (83, 119, 125, +more)].\"\n        },\n        {\n            \"summary\": \"The role of PLACEBO in understanding treatment effects\",\n            \"explanation\": \"The strategic use of PLACEBO in clinical trials across various locations, including Australia and New Zealand, has been crucial in assessing the efficacy of treatments like hydrocortisone and DROTAA. By providing a baseline for comparison, PLACEBO-controlled trials ensure that the observed effects of a treatment can be accurately attributed to the treatment itself rather than external factors. This methodology is vital for advancing medical science and improving patient care, particularly in the high-stakes area of septic shock treatment [Data: Relationships (105, 106, 110, 116, +more)].\"\n        }\n    ]\n}", "input": "\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community's key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    \"title\": \"Verdant Oasis Plaza and Unity March\",\n    \"summary\": \"The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.\",\n    \"rating\": 5.0,\n    \"rating_explanation\": \"The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.\",\n    \"findings\": [\n        {{\n            \"summary\": \"Verdant Oasis Plaza as the central location\",\n            \"explanation\": \"Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza's association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]\"\n        }},\n        {{\n            \"summary\": \"Harmony Assembly's role in the community\",\n            \"explanation\": \"Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]\"\n        }},\n        {{\n            \"summary\": \"Unity March as a significant event\",\n            \"explanation\": \"The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community's dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]\"\n        }},\n        {{\n            \"summary\": \"Role of Tribune Spotlight\",\n            \"explanation\": \"Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]\"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\n12,PLACEBO,\"PLACEBO is a control substance widely used in clinical trials to assess the effectiveness of various treatments, particularly in the context of septic shock and severe sepsis. It serves as a benchmark against which the effects of corticosteroids, such as hydrocortisone and fludrocortisone, are compared. In these studies, PLACEBO is typically administered in the same manner as the active medication, often consisting of 0.9 percent saline with or without 0.1 percent human serum albumin, to ensure that the comparison between the treatment and control groups is fair and unbiased. This approach allows researchers to accurately determine the therapeutic effect of the active drugs being tested. PLACEBO has been utilized in trials comparing its effects against hydrocortisone in patients with septic shock, including those undergoing mechanical ventilation, and in studies assessing the effectiveness of hydrocortisone plus fludrocortisone. Additionally, it has been used as a control treatment in studies evaluating the efficacy of acetaminophen and in comparison with the DrotAA treatment group. By serving as a control, PLACEBO plays a crucial role in clinical research, helping to validate the results and ensure that any observed effects are truly attributable to the treatment under investigation rather than other variables.\",18\n11,DROTAA,\"DrotAA is a treatment that was initially approved for patients with septic shock. It was the subject of a clinical trial aimed at assessing its effectiveness in reducing mortality among critically ill adults with this condition. In this study, DrotAA was compared to a placebo group, effectively making it the focus of research involving a specific group of patients receiving this treatment. However, despite its initial approval and the hopes pinned on its effectiveness, the study found that DrotAA was not beneficial for patients with septic shock. This conclusion was drawn from a comprehensive analysis of its impact, indicating that the treatment does not offer the expected survival advantage for those critically ill with septic shock.\",13\n16,AUSTRALIA,\"Australia, a country and continent, played a significant role in various medical research studies, particularly in the field of critical care and emergency medicine. It was one of the countries where a multicenter trial comparing vasopressin versus norepinephrine in septic shock patients was conducted. This highlights Australia's contribution to global efforts in improving the treatment protocols for septic shock, a condition with high mortality rates. Additionally, Australia was the primary location for the ARISE study, which focused on early intervention in septic shock, indicating its pivotal role in advancing research in sepsis management.\n\nMoreover, Australia hosted 45 sites for a trial in medical-surgical Intensive Care Units (ICUs), underscoring its extensive infrastructure and commitment to medical research. This trial, along with others mentioned, signifies Australia's involvement in critical care research, aiming to enhance patient outcomes in medical-surgical settings. The country also participated in a randomized trial comparing Early Goal-Directed Therapy (EGDT) and usual care, further demonstrating its active engagement in investigating optimal care strategies for critically ill patients.\n\nThe presence of the George Institute for Global Health in Australia is noteworthy, as it suggests the country's strategic position in global health research and its capacity to contribute to international studies. This institute likely plays a crucial role in facilitating and overseeing various trials, including those mentioned, thereby cementing Australia's status as a key player in the global health research arena.\",9\n53,ADRENAL TRIAL,A clinical trial designed to test the hypothesis that hydrocortisone results in lower mortality than placebo among patients with septic shock,10\n17,NEW ZEALAND,\"New Zealand is a country that has been actively involved in various international medical research studies, demonstrating its commitment to advancing medical knowledge and patient care. It was one of the countries where patients were recruited for a specific study, highlighting its contribution to global research efforts. Additionally, New Zealand participated in the ARISE study, hosting several centers across the country, which underscores its capability and willingness to engage in significant medical research projects. This involvement extended to having 8 medical-surgical Intensive Care Unit (ICU) sites participate in a trial, showcasing the country's substantial infrastructure and expertise in critical care research.\n\nMoreover, New Zealand was a site for the ADRENAL trial, further emphasizing its role in critical international medical research. The country's medical-surgical ICUs were also part of another study, indicating a strong and ongoing commitment to contributing to the understanding and improvement of medical-surgical intensive care. Furthermore, New Zealand was involved in a randomized trial comparing Early Goal-Directed Therapy (EGDT) and usual care, which is indicative of its active participation in research aimed at optimizing patient outcomes in critical care settings.\n\nOverall, New Zealand's involvement in these various trials and studies demonstrates its significant contribution to international medical research, particularly in the areas of critical and intensive care. The country's participation across multiple research initiatives highlights its dedication to improving healthcare outcomes both domestically and globally.\",8\n56,SAUDI ARABIA,\"Saudi Arabia was one of the countries where the ADRENAL trial was conducted, participating with three medical-surgical ICU sites. This involvement underscores its contribution to the international research effort aimed at advancing medical knowledge and practices in critical care.\",3\n55,UNITED KINGDOM,\"The United Kingdom was one of the countries where the ADRENAL trial was conducted, participating with 12 medical-surgical ICU sites. This involvement underscores the UK's active role in this international clinical research effort, highlighting its contribution to the medical field through participation in significant trials.\",3\n190,ARISE,\"ARISE, or the Australasian Resuscitation in Sepsis Evaluation, is a trial that compares Early Goal-Directed Therapy (EGDT) with usual care in the management of sepsis. This study is specifically designed to test the hypothesis that EGDT can decrease 90-day all-cause mortality among patients with septic shock in the emergency department.\",8\n174,CENTRAL RANDOMIZATION CENTER,\"The facility responsible for the random assignment of patients to either the drotrecogin alfa activated treatment or placebo in a 1:1 manner, ensuring the blinding of treatment assignments\",2\n13,EUROPE,A continent where a significant portion of the study's patients were recruited,2\n18,INDIA,A country where a portion of the study's patients were recruited,2\n21,\"MAY 12, 2010\",No Description,2\n14,NORTH AMERICA,A continent where a portion of the study's patients were recruited,2\n15,SOUTH AMERICA,A continent where a portion of the study's patients were recruited,2\n23,SERIOUS ADVERSE EVENTS,\"Recorded incidents of significant negative outcomes in patients during the clinical trial, used to evaluate the safety of DrotAA treatment\",1\n24,NONSERIOUS BLEEDING EVENTS,\"Less severe bleeding incidents recorded among patients in the clinical trial, comparing those treated with DrotAA to those receiving a placebo\",1\n51,NATIONAL HEALTH AND MEDICAL RESEARCH COUNCIL OF AUSTRALIA,\"The National Health and Medical Research Council of Australia is an organization that has funded significant research in the field of septic shock treatment. It supported the ARISE study, aimed at investigating the effectiveness of Early Goal-Directed Therapy (EGDT) in patients suffering from septic shock. Additionally, it funded a clinical trial that compared the outcomes of administering hydrocortisone versus a placebo in septic shock patients. Through these initiatives, the National Health and Medical Research Council of Australia has played a crucial role in advancing the understanding and management of septic shock, contributing valuable insights into effective treatment protocols.\",2\n54,\"GEORGE INSTITUTE FOR GLOBAL HEALTH, AUSTRALIA\",\"Sponsor of the ADRENAL trial, coordinated operational processes and conducted statistical analyses\",1\n50,INTENSIVE CARE UNIT (ICU),ICU is where patients with septic shock undergoing mechanical ventilation were treated and observed in the clinical trial,1\n189,ALFRED FOUNDATION,An organization that provided funding for the ARISE study on early septic shock treatment,1\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,combined_degree\n16,SEPTIC SHOCK,PLACEBO,\"In the study of treating septic shock, a placebo was utilized as a control to compare its effects against corticosteroids. The use of placebos was crucial in assessing the effectiveness of corticosteroids in treating patients with septic shock. This approach allowed researchers to establish a baseline for the treatment's efficacy, ensuring that any observed improvements in patients' conditions could be attributed to the corticosteroids rather than other variables. The consistent use of a placebo as a control across these studies highlights its importance in clinical research, particularly in the context of evaluating new treatments for septic shock.\",95\n12,SEPTIC SHOCK,DROTAA,\"DrotAA, once an approved treatment for septic shock, was subjected to a clinical trial aimed at assessing its effectiveness in reducing mortality among critically ill adults with this condition. However, it was ultimately found not to be beneficial for patients suffering from septic shock.\",90\n83,SEPTIC SHOCK,AUSTRALIA,Australia was one of the locations for the trial studying treatments for septic shock,86\n119,AUSTRALIA,ICU,Australia was one of the countries where the Intensive Care Unit trial took place,40\n117,PLACEBO,SEVERE SEPSIS,A placebo was used as a control in studying the treatment of severe sepsis,40\n171,HYDROCORTISONE,ADRENAL TRIAL,Hydrocortisone was one of the treatments tested in the ADRENAL trial to assess its efficacy in reducing mortality among septic shock patients,39\n125,NEW ZEALAND,ICU,New Zealand was one of the countries where the Intensive Care Unit trial took place,39\n120,AUSTRALIA,HYDROCORTISONE,Australia hosted trial sites where patients were assigned to receive hydrocortisone,38\n126,NEW ZEALAND,HYDROCORTISONE,New Zealand hosted trial sites where patients were assigned to receive hydrocortisone,37\n98,DROTAA,PLACEBO GROUP,The effectiveness of DrotAA was compared to that of the placebo group in a clinical trial involving critically ill adults with septic shock,36\n199,ICU,SAUDI ARABIA,Saudi Arabia was one of the countries where the Intensive Care Unit trial took place,34\n198,ICU,UNITED KINGDOM,The United Kingdom was one of the countries where the Intensive Care Unit trial took place,34\n90,DROTAA,PLACEBO,DrotAA and Placebo groups were compared in a clinical study to assess treatment effects,31\n116,PLACEBO,DROTRECOGIN ALFA ACTIVATED,Patients who received drotrecogin alfa activated showed greater decreases in D-dimer and interleukin-6 levels than those who received placebo,30\n110,PLACEBO,ADRENAL TRIAL,Placebo was used as a control in the ADRENAL trial to compare its effects against hydrocortisone,28\n105,PLACEBO,AUSTRALIA,\"In the study, the Placebo group included patients who were recruited from various locations, including Australia. Specifically, Placebo was assigned to patients located in medical-surgical Intensive Care Units (ICUs) across Australia. This indicates that a significant part of the research involving Placebo took place within Australian medical facilities, focusing on patients in critical care settings.\",27\n106,PLACEBO,NEW ZEALAND,\"In the study, the Placebo group included patients who were recruited from New Zealand, indicating that a portion of the participants came from this country. These patients were assigned Placebo as part of their treatment in medical-surgical Intensive Care Units (ICUs) across New Zealand. This approach was integral to the research design, highlighting New Zealand's contribution to the study through the participation of its ICUs and the recruitment of local patients for the Placebo group.\",26\n434,EGDT,ARISE,The ARISE trial compared EGDT with usual care in sepsis management,25\n94,DROTAA,AUSTRALIA,A portion of DrotAA group's patients were recruited from Australia,22\n115,PLACEBO,\"COVANCE CENTRAL LAB SERVICES, INDIANAPOLIS\",\"Covance Central Lab Services, Indianapolis, performed blood assays to measure the effects of placebo\",22\n95,DROTAA,NEW ZEALAND,A portion of DrotAA group's patients were recruited from New Zealand,21\n111,PLACEBO,UNITED KINGDOM,The United Kingdom hosted trial sites where patients were assigned to receive placebo,21\n112,PLACEBO,SAUDI ARABIA,Saudi Arabia hosted trial sites where patients were assigned to receive placebo,21\n114,PLACEBO,CENTRAL RANDOMIZATION CENTER,Placebo was assigned to patients through the Central Randomization Center as part of the study's control group protocol,20\n102,PLACEBO,EUROPE,A significant portion of Placebo group's patients were recruited from Europe,20\n107,PLACEBO,INDIA,A portion of Placebo group's patients were recruited from India,20\n108,PLACEBO,\"MAY 12, 2010\",\"Sample size increase decision on May 12, 2010, affected the Placebo group\",20\n103,PLACEBO,NORTH AMERICA,A portion of Placebo group's patients were recruited from North America,20\n104,PLACEBO,SOUTH AMERICA,A portion of Placebo group's patients were recruited from South America,20\n109,PLACEBO,O'BRIEN AND FLEMING,The O'Brien and Fleming method was used to analyze the effectiveness of placebo in the study,20\n113,PLACEBO,MANAGEMENT COMMITTEE,The Management Committee reviewed results from the study involving placebo without knowing the group assignments,20\n118,AUSTRALIA,ADRENAL TRIAL,Australia was one of the locations for the ADRENAL trial,19\n124,NEW ZEALAND,ADRENAL TRIAL,New Zealand was one of the locations for the ADRENAL trial,18\n121,AUSTRALIA,ACETAMINOPHEN,Acetaminophen was assigned to patients in medical-surgical ICUs in Australia as part of the study,18\n122,AUSTRALIA,ARISE,Most centers participating in the ARISE study are located in Australia,17\n123,AUSTRALIA,NEW ZEALAND,Both countries participated in the randomized trial comparing EGDT and usual care,17\n127,NEW ZEALAND,ACETAMINOPHEN,Acetaminophen was assigned to patients in medical-surgical ICUs in New Zealand as part of the study,17\n128,NEW ZEALAND,ARISE,New Zealand has several centers participating in the ARISE study,16\n99,DROTAA,PROTEIN C,\"The study measured the effect of DrotAA on Protein C activity, finding a significant increase in the DrotAA group compared to the placebo group\",16\n91,DROTAA,EUROPE,A significant portion of DrotAA group's patients were recruited from Europe,15\n92,DROTAA,NORTH AMERICA,A portion of DrotAA group's patients were recruited from North America,15\n93,DROTAA,SOUTH AMERICA,A portion of DrotAA group's patients were recruited from South America,15\n96,DROTAA,INDIA,A portion of DrotAA group's patients were recruited from India,15\n97,DROTAA,\"MAY 12, 2010\",\"Sample size increase decision on May 12, 2010, affected the DrotAA group\",15\n240,ADRENAL TRIAL,DENMARK,Denmark was one of the locations for the ADRENAL trial,14\n417,DROTRECOGIN ALFA ACTIVATED,CENTRAL RANDOMIZATION CENTER,Drotrecogin alfa activated was assigned to patients through the Central Randomization Center as part of the study's treatment protocol,14\n100,DROTAA,SERIOUS ADVERSE EVENTS,The occurrence of serious adverse events was compared between patients receiving DrotAA and those in the placebo group,14\n101,DROTAA,NONSERIOUS BLEEDING EVENTS,Nonserious bleeding events were more common in patients treated with DrotAA than in those receiving placebo,14\n238,ADRENAL TRIAL,UNITED KINGDOM,The United Kingdom was one of the locations for the ADRENAL trial,13\n239,ADRENAL TRIAL,SAUDI ARABIA,Saudi Arabia was one of the locations for the ADRENAL trial,13\n235,NATIONAL HEALTH AND MEDICAL RESEARCH COUNCIL OF AUSTRALIA,ADRENAL TRIAL,\"Funded the ADRENAL trial, which compared hydrocortisone and placebo in septic shock patients\",12\n237,ADRENAL TRIAL,\"GEORGE INSTITUTE FOR GLOBAL HEALTH, AUSTRALIA\",\"Sponsored the ADRENAL trial, coordinating operational processes and conducting statistical analyses\",11\n234,INTENSIVE CARE UNIT (ICU),ADRENAL TRIAL,The ADRENAL trial involved patients undergoing mechanical ventilation in the ICU,11\n439,ARISE,MONASH UNIVERSITY,Monash University is the coordinating center for the ARISE study,11\n440,ARISE,PROTOCOLIZED CARE FOR EARLY SEPTIC SHOCK,Both ARISE and ProCESS trials were part of a collaborative effort to evaluate EGDT,10\n441,ARISE,PROTOCOLIZED MANAGEMENT IN SEPSIS,ARISE and ProMISe were harmonized studies designed to address the effectiveness of EGDT,10\n236,NATIONAL HEALTH AND MEDICAL RESEARCH COUNCIL OF AUSTRALIA,ARISE,The ARISE study was funded by the National Health and Medical Research Council of Australia,10\n438,ALFRED FOUNDATION,ARISE,The ARISE study received funding from the Alfred Foundation,9\n\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:", "parameters": {"model": "gpt-4-turbo-preview", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 2000, "n": 1}, "history": null}